BACKGROUND: @entity1419 ( @entity1419 ) is associated with poor survival. This study compared the outcomes of @entity1 with unresectable @entity1419 treated with hepatic arterial infusion (HAI) plus systemic chemotherapy (SYS) with the outcomes of @entity1 treated with SYS alone. METHODS: Consecutive @entity1 with @entity1419 were retrospectively reviewed. Clinicopathologic data were reviewed. Survival rates were compared by Kaplan-Meier analysis and log-rank testing. RESULTS: Between January 2000 and August 2012, 525 @entity1 with @entity1419 were evaluated at Memorial Sloan Kettering @entity5 Center, and 236 @entity1 with unresectable @entity5 (locally advanced or metastatic) were analyzed. Disease was confined to the liver in 104 @entity1 , who underwent treatment with combined HAI and SYS (n   =   78 or 75%) or SYS alone (n   =   26 or 25%). The response rate in the combined group was better than the rate in the group receiving SYS alone, although this did not reach statistical significance (59% vs 39%, P   =   .11). Overall survival for the combined group was longer than overall survival for the @entity1 who received SYS alone (30.8 vs 18.4 months, P   <   .001), and this difference was maintained when @entity1 with @entity1600 were included in the survival analysis (29.6 months with HAI and SYS [n   =   93] vs 15.9 months with SYS [n   =   74], P   <   .001). Eight @entity1 who initially presented with unresectable @entity5 responded enough to undergo complete resection and had a median overall survival of 37 months (range, 10.4-92.3 months). CONCLUSIONS: In @entity1 with unresectable @entity1419 confined to the liver or with limited regional nodal disease, a combination of SYS and HAI chemotherapy is associated with greater survival than SYS alone. @entity5 2015.    2015 American @entity5 Society.

Unresectable XXXX : Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1600 :: ('MESH:D014388', 'Disease') :: ['portal lymph node disease'] @entity1419 :: ('MESH:C535533', 'Disease') :: ['Intrahepatic cholangiocarcinoma', 'ICC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer', 'tumors']
@entity1419 :: (MESH:C535533,Disease) :: ['intrahepatic cholangiocarcinoma']
